Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis

Virginia Martínez-Santana1 Pharmacy Department, hospital clínico Universitario de Valladolid, Valladolid, SpainCorrespondence[email protected]

E González-Sarmiento2 Internal Medicine Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain

MA Calleja-Hernández3 Pharmacy Department, Hospital Universitario Virgen de las Nieves de Granada, Granada, Spain

T Sánchez-Sánchez1 Pharmacy Department, hospital clínico Universitario de Valladolid, Valladolid, Spain

Pages 719-727 | Published online: 29 Jul 2013

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

González-GayMAAgudoMFármacos antifactor de necrosis tumoral alfa en pacientes con artritis reumatoide refractaria a tratamientos convencionales [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies]Med Clin (Barc)201013415684685 Spanish20176386
PubMed Web of Science ®Google Scholar
ScottDLWolfeFHuizingaTWRheumatoid arthritisLancet201037697461094110820870100
PubMed Web of Science ®Google Scholar
National Collaborating Centre for Chronic Conditions (UK)Rheumatoid Arthritis: National Clinical Guideline for Management and Treatment in AdultsLondon, UKRoyal College of Physicians2009
Google Scholar
SinghJAFurstDEBharatA2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care Res (Hoboken)201264562563922473917
PubMed Web of Science ®Google Scholar
GniadeckiRKragballeKDamTNSkovLComparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgarisBr J Dermatol201116451091109621219290
PubMed Web of Science ®Google Scholar
MarkensonJAGibofskyAPalmerWRPersistence with antitumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registryJ Rheumatol20113871273128121572150
PubMed Web of Science ®Google Scholar
AletahaDNeogiTSilmanAJ2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeArthritis Rheum20106292569258120872595
PubMed Web of Science ®Google Scholar
Martínez SantanaVIzquierdo NavarroMCallejaHernández MÁSánchez SánchezTSainz GilMSevere pancytopenia following etanercept administration in rheumatoid arthritisInt J Rheum Dis2012154e78e7922898233
PubMed Web of Science ®Google Scholar
Du PanSMDehlerSCiureaAZiswilerHRGabayCFinckhASwiss Clinical Quality Management PhysiciansComparison of drug retention rates and causes of drug discontinuation between antitumor necrosis factor agents in rheumatoid arthritisArthritis Rheum200961556056819405000
PubMed Web of Science ®Google Scholar
MarkatseliTEAlamanosYSaougouIVoulgariPVDrososAASurvival of TNF-alpha antagonists in rheumatoid arthritis: a long-term studyClin Exp Rheumatol2012301313822153557
PubMed Web of Science ®Google Scholar
FinckhASimardJFGabayCGuernePASCQM physiciansEvidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritisAnn Rheum Dis200665674675216339288
PubMed Web of Science ®Google Scholar
BarteldsGMWijbrandtsCANurmohamedMTAnti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort studyAnn Rheum Dis201069581782119581278
PubMed Web of Science ®Google Scholar
BusquetsNTomeroEDescalzoMÁBIOBADASER 2.0 Study GroupAge at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registryRheumatology (Oxford)201150111999200421856725
PubMed Web of Science ®Google Scholar
MarchesoniAZaccaraEGorlaRTNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practiceAnn N Y Acad Sci2009117383784619758236
PubMed Web of Science ®Google Scholar
LuratiAMarrazzaMAngelaKScarpelliniMSafety of etanercept in elderly subjects with rheumatoid arthritisBiologics201041420161980
PubMedGoogle Scholar
DeWittEMLinLGlickHAAnstromKJSchulmanKAReedSDPattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bankClin Ther200931818711880 discussion 185819808146
PubMed Web of Science ®Google Scholar
KristensenLEKapetanovicMCGülfeASöderlinMSaxneTGeborekPPredictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group RegisterRheumatology (Oxford)200847449549918316338
PubMed Web of Science ®Google Scholar
TynjäläPVähäsaloPHonkanenVLahdennePDrug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritisAnn Rheum Dis200968455255718467515
PubMed Web of Science ®Google Scholar
MihellerPKissLSLorinczyKLakatosPLAnti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?Expert Opin Biol Ther201212217919222149260
PubMed Web of Science ®Google Scholar
LorinczyKMihellerPKissSLLakatosPL[Epidemiology, predictors and clinical aspects of loss of response to biological therapy]Orv Hetil20121535163173 Hungarian [with English abstract]22275731
PubMedGoogle Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date